Qiagen publishes new sustainability report, shares backed by fresh analyst support
Published on 06/25/2026 at 17:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 17:42.
Qiagen N.V. (NL0012169213) today features with the publication of an updated sustainability report that includes detailed voluntary carbon market disclosures, according to Publicnow and Marketscreener. The stock is listed on the NYSE under the ticker QGEN, providing international investors direct exposure to the diagnostics group.
What the new report highlights
The 2026 sustainability report, published on June 25, sets out Qiagen's reporting on climate-related topics and voluntary carbon markets, according to the Publicnow disclosure. The document is part of a broader ESG communication framework that includes earlier releases on environmental and social initiatives.
Marketscreener notes the publication time as 05:38 am EDT for the latest sustainability report entry, underscoring that this is a fresh item in the company's news flow. The listing references voluntary carbon market disclosure under the label "ca ab 1305", indicating a structured reporting block within Qiagen's ESG documentation.
Analyst sentiment around Qiagen
Alongside the ESG update, analyst activity on Qiagen has remained active in June, with Morgan Stanley upgrading the stock to Overweight on June 24 and raising its price target, according to Marketscreener. The same source records DZ Bank issuing a Buy rating on June 23 and Deutsche Bank reaffirming its Buy view on June 17, reflecting a supportive sell-side stance.
MarketBeat data classify Qiagen as a medical sector stock focused on biomedical and genetic applications, and list the shares on the NYSE under the symbol QGEN. A separate overview compiled by Marketscreener shows an average analyst target price of 43.96 USD, above the latest close, summarizing a broadly positive consensus on the stock.
All news and analysis on the Qiagen shares
Further background, data and ad-hoc releases on Qiagen help investors track results, guidance changes and ESG disclosures around the NYSE-listed diagnostics stock.
The product behind the stock
Qiagen generates revenue primarily by supplying sample preparation and testing solutions for molecular diagnostics and life science research, with flagship products such as QIAcuity digital PCR instruments and related assays. The company also offers nucleic acid extraction kits and automation platforms used in hospitals, laboratories and biotech facilities worldwide.
Where the stock trades today
Qiagen shares (NL0012169213) trade on the NYSE under the ticker QGEN, with the last close recorded at 38.75 USD on June 24, 2026 at 15:59 Eastern time, according to MarketBeat data.
Qiagen in brief
- Company: QIAGEN N.V.
- ISIN: NL0012169213
- WKN: A41HBE
- Ticker: QGEN
- Trading venue: NYSE
- Price (as of 2026-06-24, 15:59): 38.75 USD
- Market cap: 8.93 billion USD (as of 2026-06-24)
- Sector / industry: Medical, biotechnology and genetic diagnostics
- Index membership: Not a member of major headline indices such as S&P 500 or NASDAQ-100, but part of sectoral and thematic indices tracked by specialist providers
- Next earnings date: not officially scheduled
Disclaimer: This article is for information purposes only and does not constitute investment advice, a buy or sell recommendation, or a solicitation to purchase any financial instrument. All data are based on sources cited and may change over time.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
